01569: Evaluation of GS-9219 in Canine Cutaneous Lymphoma
Principal Investigator: Dr. Douglas H Thamm, VMD
Institution: Colorado State University
Total Grant Amount: \$37,844.00. SCARF contributed \$2500.
Grant Status: Closed
Final Research Summary:
Canine lymphoma is one of the most common cancers encountered in veterinary oncology. While most canine multicentric lymphoma patients initially respond to currently available chemotherapy protocols, response rates are considerably lower in patients with cutaneous T cell lymphoma (CTCL), and generally brief in duration. We previously demonstrated the effectiveness of the novel cancer drug GS-9219 in dogs with multicentric lymphoma, in which 100% of chemotherapy-naïve and 60% of chemotherapy-relapsed patients experienced responses. One of the observed toxicities in GS-9219 treated dogs was a skin change characterized by hair loss, redness and itching, implying significant delivery of GS-9219 to the skin. Given the lack of durable effective therapy for canine CTCL, and the demonstrated antilymphoma activity and apparent skin accumulation of GS-9219, we propose to evaluate the effectiveness of GS-9219 in canine CTCL through the completion of a phase-II clinical trial. Dogs with chemotherapy-naive or relapsed, histologically confirmed CTCL will receive GS- 9219 as a 30-minute intravenous infusion once every 21 days. The primary endpoint will be objective response rate. Secondary endpoints will include progression-free survival, as well as acute and cumulative adverse effects. Successful demonstration of efficacy of GS-9219 against canine CTCL would provide an important drug in the veterinarian’s armamentarium against this challenging disease.
Vail DM, Thamm DH et al. Assessment of GS-9219 in a pet dog model of non-Hodgkin’s lymphoma. 2009. Clin Cancer Res 15:3503-3510.